We are live on ! Find out more
DYN icon

Dyne Therapeutics

200 hedge funds and large institutions have $2.63B invested in Dyne Therapeutics in 2024 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 68 increasing their positions, 63 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

12% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 34

8% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 63

0% more funds holding

Funds holding: 200200 (0)

2.29% less ownership

Funds ownership: 111.98%109.69% (-2.3%)

30% less funds holding in top 10

Funds holding in top 10: 107 (-3)

35% less capital invested

Capital invested by funds: $4.03B → $2.63B (-$1.4B)

65% less call options, than puts

Call options by funds: $3.57M | Put options by funds: $10.3M

Holders
200
Holders Change
Holders Change %
0%
% of All Funds
2.63%
Holding in Top 10
7
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-30%
% of All Funds
0.09%
New
38
Increased
68
Reduced
63
Closed
34
Calls
$3.57M
Puts
$10.3M
Net Calls
-$6.72M
Net Calls Change
-$8.69M
Name Holding Trade Value Shares
Change
Change in
Stake
AVLSA
1
Atlas Venture Life Science Advisors
Massachusetts
$189M -$23.1K -782 -0%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$188M -$30.5M -1,029,766 -11%
BlackRock
3
BlackRock
New York
$187M +$4.59M +155,288 +2%
Janus Henderson Group
4
Janus Henderson Group
United Kingdom
$174M +$16.7M +566,146 +8%
Vanguard Group
5
Vanguard Group
Pennsylvania
$158M -$4.74M -160,211 -2%
RCM
6
RA Capital Management
Massachusetts
$150M
FIS
7
FCPM III Services
Netherlands
$129M -$14.5M -491,223 -8%
RI
8
RTW Investments
New York
$123M -$47.3M -1,600,000 -23%
State Street
9
State Street
Massachusetts
$87.6M +$2.23M +75,524 +2%
Citadel Advisors
10
Citadel Advisors
Florida
$67.4M -$2.3M -77,759 -3%
TCM
11
TCG Crossover Management
California
$62.4M
T. Rowe Price Associates
12
T. Rowe Price Associates
Maryland
$56.6M -$6.92M -233,841 -9%
Holocene Advisors
13
Holocene Advisors
New York
$55.3M +$10.8M +365,521 +18%
VA
14
VR Adviser
New York
$51.2M
DTC
15
Deep Track Capital
Connecticut
$47.1M -$37.9M -1,282,000 -39%
Adage Capital Partners
16
Adage Capital Partners
Massachusetts
$45.9M -$13.4M -452,972 -19%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$44.5M +$826K +27,916 +2%
JFG
18
Jefferies Financial Group
New York
$42.4M +$53.2M +1,800,000 New
SL
19
Siren LLC
Connecticut
$31.7M +$6.29M +212,792 +19%
Franklin Resources
20
Franklin Resources
California
$31.2M -$553K -18,697 -1%
O
21
OrbiMed
New York
$28.9M +$15.3M +518,680 +73%
Jennison Associates
22
Jennison Associates
New York
$28.6M -$3.99M -135,037 -10%
VC
23
Vivo Capital
California
$26.3M
SI
24
Sofinnova Investments
California
$25.2M +$8.86M +299,428 +39%
Federated Hermes
25
Federated Hermes
Pennsylvania
$24.9M -$4.76M -160,929 -13%

DYN Hedge Fund Activity: Q4 2024 in Review

200 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Dyne Therapeutics (DYN) for Q4 2024, worth a combined $2.63B — down 35% from $4.03B a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new DYN positions and 34 closed out — a net gain of 4 holders — while 68 added to existing stakes and 63 trimmed.

The largest buyer was Jefferies Financial Group, opening a new position worth an estimated $53.2M. The largest seller was RTW Investments, cutting an estimated $47.3M.

  • 200 institutional investors held Dyne Therapeutics (DYN) as of Q4 2024, unchanged from Q3 2024.
  • Funds reported $2.63B of Dyne Therapeutics stock for Q4 2024, down 35% quarter-over-quarter.
  • 38 funds opened new Dyne Therapeutics positions in Q4 2024 and 34 closed out, a net change of +4 holders.
  • The largest Dyne Therapeutics buyer in Q4 2024 was Jefferies Financial Group, an estimated $53.2M added.
  • The largest Dyne Therapeutics seller in Q4 2024 was RTW Investments, an estimated $47.3M sold.

Based on aggregated 13F filings for Q4 2024.